Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2023 16:05 ET | Source: Cavco Industries, Inc.

Cavco Releases First HUD-Approved Manufactured Duplex Homes

PHOENIX, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cavco Industries, Inc. (Nasdaq: CVCO) (“Cavco” or the “Company”) is proud to announce a significant innovation in the manufactured home industry with the...
November 03, 2023 10:46 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape ..."
October 13, 2023 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for...
August 10, 2023 06:00 ET | Source: Research Nester

Duplex Stainless Steel Market revenue to cross USD 11.11 Billion by 2035, says Research Nester

New York, Aug. 10, 2023 (GLOBE NEWSWIRE) -- The global duplex stainless steel market size is predicted to grow at a CAGR of over ~7.7% from 2023 to 2035. The market is projected to garner a revenue...
September 21, 2020 08:00 ET | Source: Retrophin, Inc.

Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety...
February 24, 2020 16:01 ET | Source: Retrophin, Inc.

Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results

Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings Full year 2019 net product sales of $175 million SAN DIEGO, Feb. 24,...